Welcome to our dedicated page for Vtv Therapeutics SEC filings (Ticker: VTVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The vTv Therapeutics Inc. (VTVT) SEC filings page on Stock Titan provides access to the company’s official disclosures as a Nasdaq-listed issuer of Class A common stock. vTv Therapeutics is a late-stage biopharmaceutical company focused on oral, small molecule drug candidates for diabetes and other chronic diseases, with a clinical pipeline led by cadisegliatin (TTP399), a liver-selective glucokinase activator in Phase 3 development for type 1 diabetes.
Through this page, users can review current and historical filings submitted to the U.S. Securities and Exchange Commission, including Forms 8‑K that detail material events. Recent 8‑K filings describe quarterly financial results, private placement transactions involving common stock and warrants, and participation in investor conferences. For example, vTv Therapeutics has filed 8‑Ks outlining an approximately $80 million private placement of Class A common shares and pre-funded warrants, along with accompanying warrants, and has disclosed registration rights agreements for the resale of these securities.
Investors interested in vTv Therapeutics’ development of cadisegliatin and other small molecules can use this filings page to locate quarterly and annual reports (Forms 10‑Q and 10‑K when available), which typically summarize research and development spending, cash position, and risk factors associated with drug development. The page also surfaces current reports on material events (Form 8‑K), which may include updates on financing arrangements, clinical milestones, and other significant corporate actions.
Stock Titan complements the raw SEC documents with AI-powered summaries designed to highlight key points from lengthy filings, helping readers quickly understand topics such as capital structure changes, contract liabilities, warrant terms, and the financial context for ongoing clinical trials. Users can also track filings that relate to equity issuances and warrants, which are important for understanding potential dilution and funding of the cadisegliatin program.
By reviewing vTv Therapeutics’ SEC filings in one place, investors and researchers can follow how the company reports its financial condition, capital-raising activities, and material developments tied to its late-stage diabetes-focused pipeline.
vTv Therapeutics Inc. reported that its subsidiary vTv Therapeutics LLC entered into a Second Amendment to its license agreement with Newsoara Biopharma Co., Ltd. on January 30, 2026. The amendment expands Newsoara’s rights to vTv’s PDE4 inhibitor HPP737 to cover all countries.
In return, Newsoara will pay an upfront fee of
vTv Therapeutics Inc. reported Q3 2025 results. The company recorded no revenue, with operating expenses of $10.7 million (research and development $7.0 million; general and administrative $3.7 million), leading to a net loss attributable to vTv of $8.7 million and basic/diluted loss per share of $1.08.
Liquidity improved, with cash and cash equivalents $98.5 million at September 30, 2025, supported by an August private placement that brought aggregate gross proceeds of approximately $80.0 million (net financing cash inflow $77.8 million). Management now indicates there is no longer substantial doubt about the company’s ability to continue as a going concern for at least twelve months from issuance.
Development advanced: the FDA removed the cadisegliatin clinical hold on March 14, 2025, and the CATT1 Phase 3 protocol was shortened to six months; top‑line data are expected in the second half of 2026. Shares outstanding were 3,938,018 Class A and 241 Class B as of November 6, 2025.
vTv Therapeutics Inc. furnished an 8‑K announcing financial results for the fiscal quarter ended September 30, 2025. The company issued a press release, attached as Exhibit 99.1, detailing its results.
The report states the information, including Exhibit 99.1, is being furnished and not filed under the Exchange Act, which limits applicability of certain liabilities and incorporation by reference unless specifically cited.
vTv Therapeutics Inc. filed an S-3 shelf registering up to 15,876,640 shares of Class A common stock and related warrants and pre-funded warrants. The filing reports positive clinical data for cadisegliatin from the SimpliciT-1 trial showing a 40% reduction in severe and symptomatic hypoglycemia and a statistically significant improvement in HbA1c versus placebo, with fewer abnormal serum or urine ketone findings. A Phase 1 mechanistic study found no increased ketoacidosis risk during acute insulin withdrawal. The company reported that an ADME radiochromatographic signal was identified as an experimental artifact and that the FDA lifted a clinical hold on March 14, 2025, allowing clinical development to resume in Q2 2025. The registration discloses Pre-Funded Warrants exercisable at $0.01 and Common Warrants with a weighted average exercise price of $22.98. The filing incorporates audited 2024 financials with Ernst & Young LLP noting an explanatory paragraph raising substantial doubt about the company’s ability to continue as a going concern.
Reporting persons led by Dr. Srinivas Akkaraju disclosed a material holding in vTv Therapeutics Inc. The amendment describes final closing of an August 2025 private placement on September 22, 2025, in which Samsara Opportunity Fund paid $15.0 million to acquire 106,000 Class A shares plus Pre-Funded Warrants exercisable for up to 877,214 shares and Common Warrants exercisable for up to 983,214 shares. Aggregate beneficial ownership reported for the group equals 343,223 shares, representing 9.9% of Class A stock on the basis stated. Certain warrant exercises are blocked to prevent beneficial ownership exceeding 9.99%.
Srinivas Akkaraju, a director of vTv Therapeutics (VTVT), reported on Form 4 that related investment vehicles managed or controlled by him participated in a securities purchase closed on September 22, 2025. Samsara Opportunity Fund, L.P. purchased 106,000 shares of Class A common stock at $15.265 per share and received pre-funded warrants exercisable for up to 877,214 shares plus common warrants exercisable for up to 983,214 shares. Separately, securities held by Samsara BioCapital, L.P. include 206,784 shares of Class A common stock, pre-funded warrants exercisable for up to 1,548,101 shares, and common warrants exercisable for up to 655,523 shares. The pre-funded warrants are exercisable at $0.01 with no expiration; common warrants have an exercise price of $22.71 and expire by September 3, 2030 or upon certain conditions. Ownership is reported as indirect through the named investment entities and the reporting person disclaims direct beneficial ownership except to the extent of his pecuniary interest.
vTv Therapeutics Inc. filed a current report describing its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference. On September 10, 2025, the company will join a fireside chat scheduled from 2:35 to 3:10 p.m. EST, available as a live audio webcast and on demand.
The company notes that a link to the webcast will be posted on its website. This communication is furnished under Regulation FD and is expressly stated not to be deemed “filed” for purposes of Section 18 of the Exchange Act or incorporated by reference into other securities filings.
Trails Edge filing discloses a 9.9% position in vTv Therapeutics (VTVT) as of August 29, 2025. The Filers—Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai—report beneficial ownership of 340,536 shares of vTv common stock, comprised of 231,000 shares held directly and 109,536 shares underlying pre-funded warrants. The filing explains that additional warrants exist but are subject to an issuance limitation that prevents exercise to the extent it would push ownership above 9.99%. Trails Edge Capital is the investment manager and Mr. Yehudai is the Chief Investment Officer exercising voting and investment discretion. The statement affirms the shares were not acquired to change or influence control of the issuer. The issuer's principal office is listed in High Point, North Carolina.
Multiple affiliated investment vehicles disclosed a near-10% stake in vTv Therapeutics Inc. The Reporting Persons collectively beneficially own 348,083 shares equivalent, composed of 163,000 Class A Shares and 185,083 warrants and pre-funded warrants, representing 9.99% of the outstanding Class A common stock. Invus Public Equities directly holds 143,440 Shares plus warrants and pre-funded warrants; Avicenna Life Sci Master Fund holds 19,560 Shares plus related warrants. A Beneficial Ownership Limitation prevents exercise of warrants that would raise ownership above 9.99%, and affiliated advisors and entities are disclosed as having control relationships that may attribute ownership across the group.